Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update (Q38210319)

31 August 2017

Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients: a clinical update (English)

1 reference

31 August 2017

Pseudomonas aeruginosa

0 references

0 references

1 reference

1

Jean-Louis Vincent

1 reference

31 August 2017

1 January 2014

1 reference

31 August 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

31 August 2017

9

1 reference

31 August 2017

4

1 reference

31 August 2017

457-463

1 reference

Clinical and economic consequences of ventilator-associated pneumonia: a systematic review.

31 August 2017

1 reference

Sepsis in European intensive care units: results of the SOAP study.

21 January 2018

1 reference

International study of the prevalence and outcomes of infection in intensive care units

21 January 2018

1 reference

Pseudomonas aeruginosa: resistance to the max

21 January 2018

1 reference

Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection.

21 January 2018

1 reference

Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results

21 January 2018

1 reference

A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients

21 January 2018

1 reference

Controlled trials of a polyvalent pseudomonas vaccine in burns

21 January 2018

1 reference

The epidemiology of sepsis in the United States from 1979 through 2000

21 January 2018

1 reference

Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients

21 January 2018

1 reference

Thirteen years of antibiotic susceptibility surveillance of Pseudomonas aeruginosa from intensive care units and urology services in the Netherlands.

21 January 2018

1 reference

The flagellum of Pseudomonas aeruginosa is required for resistance to clearance by surfactant protein A.

21 January 2018

1 reference

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

21 January 2018

1 reference

Full virulence of Pseudomonas aeruginosa requires OprF

21 January 2018

1 reference

Role of the novel OprD family of porins in nutrient uptake in Pseudomonas aeruginosa

21 January 2018

1 reference

Role of Pseudomonas aeruginosa peptidoglycan-associated outer membrane proteins in vesicle formation

21 January 2018

1 reference

Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5.

21 January 2018

1 reference

Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients

21 January 2018

1 reference

Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation

21 January 2018

1 reference

Flagella and pili-mediated near-surface single-cell motility mechanisms in P. aeruginosa

21 January 2018

1 reference

Protein Secretion Systems in Pseudomonas aeruginosa: An Essay on Diversity, Evolution, and Function

21 January 2018

1 reference

Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung

21 January 2018

1 reference

Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia.

21 January 2018

1 reference

Adenylate cyclase activity of Pseudomonas aeruginosa ExoY can mediate bleb-niche formation in epithelial cells and contributes to virulence.

21 January 2018

1 reference

Pseudomonas aeruginosa virulence and therapy: evolving translational strategies

21 January 2018

1 reference

Quorum-sensing genes in Pseudomonas aeruginosa biofilms: their role and expression patterns

21 January 2018

1 reference

Quorum sensing between Pseudomonas aeruginosa biofilms accelerates cell growth

21 January 2018

1 reference

The multiple signaling systems regulating virulence in Pseudomonas aeruginosa

21 January 2018

1 reference

Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent

21 January 2018

1 reference

Pseudomonas aeruginosa - a phenomenon of bacterial resistance

21 January 2018

1 reference

Vaccines and immunotherapy against Pseudomonas aeruginosa

21 January 2018

1 reference

Recent developments for Pseudomonas vaccines

21 January 2018

1 reference

Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

21 January 2018

1 reference

Pharmacokinetics and safety profile of the human anti-Pseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers

21 January 2018

1 reference

Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia.

21 January 2018

1 reference

The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem

21 January 2018

1 reference

40 years on: have we finally got a vaccine for Pseudomonas aeruginosa?

21 January 2018

1 reference

Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia

21 January 2018

1 reference

Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.

21 January 2018

1 reference

Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FMB.14.10

1 reference

31 August 2017

1 reference

PubMed ID

24810345